t(11;14)(q13;q32) in multiple myeloma Huret JL, Laï JL

Gene Section Review

Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 412

Atlas of Genetics and Cytogenetics in Oncology and Haematology

OPEN ACCESS JOURNAL AT INIST-CNRS

PTPN1 (protein tyrosine phosphatase, non-receptor type 1) Giuseppe Leuzzi, Alberto Calderone, Luisa Castagnoli

Department of Biology, University of Rome Tor Vergata, Rome, Italy (GL, AC, LC)

Published in Atlas Database: January 2012

Online updated version : http://AtlasGeneticsOncology.org/Genes/PTPN1ID41909ch20q13.html DOI: 10.4267/2042/47339

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity Other names: PTP1B

HGNC (Hugo): PTPN1

Location: 20q13.13

Local order: According to NCBI Map Viewer, PTPN1 gene is located between: LOC284751, COX6CP2 (cytochrome c oxidase subunit VIc pseudogene 2) (in centromeric position), MIR645 (microRNA 645) and FAM65c (family with sequence similarity 65, member c) (in telomeric position).

DNA/RNA Note PTPN1 is located at 49126891-49201299 bp; chromosome 20, strand +, Unigene cluster Hs.417549, Entrez gene Id 57570. The gene is located in a genomic region that has been identified in multiple linkage studies as a QTL for obesity and diabetes (Ghosh et al., 1999; Soro et al., 2002).

Description In humans, PTPN1, the gene coding for PTP-1B, is located on human chromosome 20q13. The 10 exons of the gene span more than 74 kb of genomic DNA, in the centromere-to-telomere orientation. The promoter region of PTPN1 gene contains no TATA box, but multiple GC rich sequences in which a number of consensus SP-1 binding sites are present (Forsell et al., 2000).

Transcription The open reading frame includes 1305 bp and codes for a protein of 435 amino acids (Olivier et al., 2004). According to Ensembl, PTPN1 gene has two alternative transcripts: - PTPN1-001: 10 exons, 3529 bp mRNA, 435 amino acids; - PTPN1-201: 9 exons, 1634 bp mRNA, 362 amino acids. (Ensembl database: Ensembl Reference Sequence: ENST00000371621 (PTPN1-001), ENST00000541713 (PTPN1-201)).

Pseudogene No human pseudogene for PTPN1 has been identified.

Protein Description Size: 435 amino acids; 49967 Da.

Expression PTP1B is expressed abundantly.

Localisation Endoplasmic reticulum membrane; peripheral membrane protein; cytoplasmic side.

Function Belongs to the protein-tyrosine phosphatase family. Non-receptor class 1 subfamily; IUBMB enzyme nomenclature: EC 3.1.3.48. PTP1B (P18031 in UniProtKB) has an N-terminal

PTPN1 (protein tyrosine phosphatase, non-receptor type 1) Leuzzi G, et al.

Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 413

catalytic phosphatase domain (residues 1-300) followed by a regulatory region of about 80-100 residues and a membrane localization domain (residues 400-435) that tethers the enzyme to the cytoplasmic face of the endoplasmic reticulum (ER). The enzymatic activity is tightly controlled by means of four described mechanisms: oxidation, phosphorylation, SUMOylation, and proteolysis. PTP1B activity is regulated in vivo by reversible oxidation involving Cys 215 at its active site and SUMOylation at two lysines (i.e., 335 and 347). Serine or tyrosine phosphorylation can affect protein interactions (Yip et al., 2010).

Mutations Note The 1484insG variation (OMIM variation (176885.0001)) (Meshkani et al., 2007), the single-nucleotide polymorphism (SNP) 981CT (Mok et al., 2002), VS6+G82A polymorphism, G82G, Pro387Leu variant (Ukkola et al., 2005).

Implicated in Various diseases and cancers Note PTP1B is involved in direct/enzymatic or indirect interactions with several proteins. In the figure, the

PTPN1/PTP1B human interactome is drawn. Each protein is depicted as circle whose color refers to the human pathology where the interaction with PTP1B is found misregulated. The numbers refer to the PMID of the articles supporting the interaction data.

Oncogenesis PTP1B as a putative tumor suppressor. Several evidences support the notion that PTP1B is a negative regulator of cell growth, although loss of function mutations and gene silencing have not been found in human cancer. PTP1B dephosphorylates and inactivates a number of receptor protein tyrosine kinases, including the EGF (epidermal growth factor) and PDGF (platelet-derived growth factor) receptors and therefore can exert a suppressive action on growth factor cell signaling (Haj et al., 2002). Ferrari et al. have used HEK293 human embryonic kidney cell line, stimulated with a high EGF concentration and observed that overexpression of PTP1B reduces EGF-dependent ERK activation, by dephosphorylating phospho-tyrosines of the scaffold protein GAB1. These phospho-tyrosines are the docking sites of the ERK activator SHP2 phosphatase. On the contrary, inhibition of the PTP1B enzymatic activity has an opposite effect, allowing SHP2 to localize on GAB1 and exert its positive role on RAS/ERK signaling (Ferrari et al., 2010).

The PTP1B human interactome. Interactions are categorized according to OLS (The Ontology Lookup Service) and according to evidence collected in the major PPI databases (Protein-Protein Interaction Databases). Interactions indicated with dashed lines are enzymatic reaction. Interactions indicated with continuous lines are interactions related to methodologies like: two hybrid, protein complementation assay, affinity chromatography technology and similar methodologies that imply a physical interaction. According to Mentha - the Interactome browser.

PTPN1 (protein tyrosine phosphatase, non-receptor type 1) Leuzzi G, et al.

Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 414

In 2006, Akasaki et al. proposed a molecular mechanism to explain the involvement of PTP1B in the proapoptotic effect caused by troglitazone, an anti-diabetic drug, now withdrawn by Food and Drug Administration that could represent a promising drug for adjuvant therapy of glioma and other highly migratory tumors. The troglitazone is a pharmacological agonist of the peroxisome proliferator-activated receptor-gamma (PPARgamma), that acts, in synergy with apoptosis inducing agents, to facilitate caspase signaling, in human glioma cells. Troglitazone activates PTP1B, which subsequently reduces phosphotyrosine 705 in the prosurvival protein STAT3. Reduction of pY705-STAT3 in glioma cells causes down-regulation of anti-apoptotic proteins FLIP (FLICE-inhibitory protein) and Bcl-2 (Akasaki et al., 2006; Coras et al., 2007; Lund et al., 2005). PTP1B can also contribute to cell-cell association since it is bound to the cytoplasmic domain of N-cadherin and it is responsible for dephosphorylating phospho-tyrosine residues belonging to beta-catenin, thus maintaining the cadherin-actin connection and cell adhesion (Balsamo et al., 1998). Moreover, PTP1B is required for the trafficking of the N-cadherin precursor from the endoplasmic reticulum to the Golgi apparatus, because, by dephosphorylating the p120 catenin, it promotes the binding between N-cadherin precursor and p120 catenin, an interaction required for a correct anterograde movement (Hernández et al., 2010)

Autoimmunity and B-cell lymphomas Note Lu et al. have reported a novel negative feedback loop involving the anti-tumor IL-4/Jak/STAT6 signaling and the phosphatase PTP1B, in a type of aggressive non-Hodgkin lymphoma, the activated B-cell-like diffuse large B-cell lymphomas (ABC-DLBCL). In this lymphoma, STAT6 is dephosphorylated in the nucleus and in the cytoplasm and the authors have demonstrated, by immunohistochemical analysis of 371 cases of hematolymphoid malignancies, that PTP1B is more commonly expressed in the ABC-like DLBCL. Since ABC-like DLBCL express also higher levels of TCPTP (an ubiquitous tyrosine-specific phosphatase in which the catalytic domain has 72% identity to that of PTP1B), compared with other lymphomas (GCB-like DLBCL), the authors suggested that both the phosphatases PTP1B and TCPTP regulate STAT6 signaling, by dephosphorylating STAT6 in the cytoplasm and in the nucleus, respectively. This result identifies an important regulatory loop in neoplasia, where IL-4 induces PTP1B, which suppresses IL-4 induced STAT6 signaling, and suggests that augmentation of PTP1B expression may render tumor cells insensitive to the anti-tumor effect of the IL-4/Jak/STAT6 pathway (Lu et al., 2008).

Breast cancer Note PTP1b as a tumor promoter. In clinical samples, it has been long noted that PTP1B expression increases in several human breast and ovarian cancers (Wiener et al., 1994b). Recently, several studies have pointed out a positive role of PTP1B in oncogenic properties of breast cancer cells as well as in the sensitization or resistance of cancer cells to apoptosis induced by cytotoxic compounds. PTP1B positively regulates ErbB2-induced tumorigenesis at the level of the Ras/MAP Kinase, probably by dephosphorylating p62Dok on Tyr398, thus blocking its association with the Ras GTPase-activating protein p120 RasGAP, the Ras inhibitor (Dubé et al., 2004; Mertins et al., 2008). PTP1B is also described as a positive regulator of human breast adenocarcinoma (MCF-7) cell line proliferation. Also in this case, PTP1B exerts a positive effect on ERK phosphorylation by a mechanism independent of the regulation of RasGAP, of the phosphorylation state of p62Dok Tyr398 or of the phosphorylation of STAT3 on Tyr705. In fact, in MCF-7 cells resistant to tamoxifen, PTP1B and the highly similar TC-PTP phosphatase are overexpressed, while ERK and STAT3 are hyperphosphorylated. This result indicates PTP1B as a new target for the treatment of tamoxifen-resistant breast cancers (Blanquart et al., 2009). PTP1B is shown to be required for ErbB2-mediated transformation of MCF-10A human breast epithelial cells and its overexpression alters acinar morphogenesis via activation of Src. MCF-10A cells are immortalized, nontransformed cells derived from a reduction mammoplasty, which form organized acini when grown within three-dimensional matrices such as reconstituted basement membrane. In this model, transformation causes characteristic changes in acinar morphogenesis, proliferation, and luminal apoptosis, that resemble those seen in human ductal carcinoma of the breast. In MCF-10A, PTP1B expression is increased by ErbB2 and PTP1B activates the tyrosine kinase Src by dephosphorylation of its repressing tyrosine 527 (Arias-Romero et al., 2009). This result is in accordance with previous studies that analyzed frozen sections from 29 human mammary tumors and demonstrated a significant association between PTP1B overexpression and breast cancer (P < 0,038) and between the overexpression of PTP1B and the overexpression of ErbB-2 (P < 0,006) (Wiener et al., 1994b). An analogous study found a correlation between increased PTP1B overexpression, statistically associated with human ovarian carcinoma, and the expression of ErbB-2, EGFR, and CSFR growth factor receptor protein tyrosine kinases (Wiener et al., 1994a).

PTPN1 (protein tyrosine phosphatase, non-receptor type 1) Leuzzi G, et al.

Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 415

Susceptibility to insulin resistance and metabolic syndrome Note Protein tyrosine phosphatase PTP1B negatively regulates insulin and leptin signaling. Therefore, it is considered a promising drug target for enhancing insulin sensitivity in type 2 diabetes and controlling body mass in obesity. PTP1B, in fact, dephosphorylates activating phospho-tyrosines present on the Insulin receptor molecule (INSR; OMIM 147670) in hepatocytes and myocytes, thus inhibiting insulin signaling (Ng, 2011). The activation segment within the insulin receptor contains three sites of autophosphorylation, pTyr-1158, pTyr-1162, and pTyr-1163. PTP1B exhibited a striking affinity preference for the bis- and the tris-phosphorylated peptides, with KMs of 14 and 8 µM, respectively, compared to the mono-phosphorylated peptides, where the KMs were above 100 µM, but PTP1B preferentially dephosphorylates pTyr-1162 within the tris-phosphorylated segment (Salmeen et al., 2000). When PTP1B is overexpressed, it plays a role in insulin resistance (Ahmad et al., 1997; Salmeen et al., 2000). Di Paola et al. have identified, in the 3' untranslated region of the PTP1B gene, a 1484insG variation that is associated with several features of insulin resistance and metabolic syndrome. The 1484insG allele causes PTP1B overexpression, probably by increasing PTP1B mRNA stability (Di Paola et al., 2002). Mok et al. identified a single-nucleotide polymorphism in exon 8, designated 981CT, that could be associated with a reduced risk of diabetes since subjects with the PTP1B 981T/981C were 40% less likely to present an impaired glucose tolerance or type II diabetes (Mok et al., 2002). The PTPN1 Pro387Leu missense variant was associated with lower glucose tolerance and with a 3.7-fold increased risk of type 2 diabetes (Ukkola et al., 2005). PTPN1 IVS6+G82G homozygotes showed higher levels of all measures of adiposity. The G82A heterozygotes are potentially at higher risk for type 2 diabetes (Ukkola et al., 2005). Obesity research is aiming at understanding and targeting the neural signaling pathways that control energy balance. The adipocyte-secreted hormone leptin acts in the brain to decrease appetite and increase energy expenditure via the simultaneous suppression of hypothalamic neurones that synthesize agouti-related protein (AgRP) and the stimulation of neurone producing proopiomelanocortin (POMC). Unfortunately, leptin cannot be used to control obesity due to the development of a resistance to leptin. PTP1B has thus became an interesting target because of its negative regulatory role on leptin signaling, mediated through a direct and selective dephosphorylation of the two main signaling molecules downstream of the activated leptin receptor, JAK2 and STAT3 (Lund et al., 2005). Moreover, interactions between the gene variants of PTPN1 and leptin receptor have been shown

to contribute to the phenotypic variability of insulin sensitivity (Ukkola et al., 2005). A recent study conducted on a sample of families with two or more members with type 2 diabetes, has revealed an association of common PTPN1 SNPs and haplotypes with coronary artery calcification (CorCP), which is a surrogate measure of atherosclerosis and subclinical cardiovascular disease. The authors observed that PTPN1 haplotype GACTTCAGO, associated with type 2 diabetes, was also significantly associated with increased CorCP (Burdon et al., 2006). The Stanford Asia-Pacific Program for Hypertension and Insulin Resistance (SAPPHIRe) cohort study has investigated the possible role of common genetic variations in PTPN1 on the development of hypertension, hyperlipidemia and obesity. The study has analyzed common (> 2%) sequence variation of PTPN1 in Japanese and Chinese descent, in order to study the association of individual SNPs and resulting haplotypes with quantitative phenotypes characteristic of the metabolic syndrome (Olivier et al., 2004). Because of the regulating properties of PTP1B, efforts are made to produce small molecules able to target the active site of the phosphatase in order to treat diabetes. Recently Haque et al. have isolated a single chain variable fragment antibody that stabilizes the inactive form of PTP1B thereby inhibiting its catalytic activity. This small molecule could inspire development of inhibitors that stabilize the inactive conformation of PTP1B (Haque et al., 2011).

References Wiener JR, Hurteau JA, Kerns BJ, Whitaker RS, Conaway MR, Berchuck A, Bast RC Jr. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am J Obstet Gynecol. 1994a Apr;170(4):1177-83

Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC Jr. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst. 1994b Mar 2;86(5):372-8

Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein BJ. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism. 1997 Oct;46(10):1140-5

Balsamo J, Arregui C, Leung T, Lilien J. The nonreceptor protein tyrosine phosphatase PTP1B binds to the cytoplasmic domain of N-cadherin and regulates the cadherin-actin linkage. J Cell Biol. 1998 Oct 19;143(2):523-32

Ghosh S, Watanabe RM, Hauser ER, Valle T, Magnuson VL, Erdos MR, Langefeld CD, Balow J Jr, Ally DS, Kohtamaki K, Chines P, Birznieks G, Kaleta HS, Musick A, Te C, Tannenbaum J, Eldridge W, Shapiro S, Martin C, Witt A, So A, Chang J, Shurtleff B, Porter R, Kudelko K, Unni A, Segal L, Sharaf R, Blaschak-Harvan J, Eriksson J, Tenkula T, Vidgren G, Ehnholm C, Tuomilehto-Wolf E, Hagopian W, Buchanan TA, Tuomilehto J, Bergman RN, Collins FS, Boehnke M. Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2198-203

PTPN1 (protein tyrosine phosphatase, non-receptor type 1) Leuzzi G, et al.

Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 416

Forsell PA, Boie Y, Montalibet J, Collins S, Kennedy BP. Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes. Gene. 2000 Dec 30;260(1-2):145-53

Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell. 2000 Dec;6(6):1401-12

Di Paola R, Frittitta L, Miscio G, Bozzali M, Baratta R, Centra M, Spampinato D, Santagati MG, Ercolino T, Cisternino C, Soccio T, Mastroianno S, Tassi V, Almgren P, Pizzuti A, Vigneri R, Trischitta V. A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet. 2002 Mar;70(3):806-12

Haj FG, Verveer PJ, Squire A, Neel BG, Bastiaens PI. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science. 2002 Mar 1;295(5560):1708-11

Mok A, Cao H, Zinman B, Hanley AJ, Harris SB, Kennedy BP, Hegele RA. A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree. J Clin Endocrinol Metab. 2002 Feb;87(2):724-7

Soro A, Pajukanta P, Lilja HE, Ylitalo K, Hiekkalinna T, Perola M, Cantor RM, Viikari JS, Taskinen MR, Peltonen L. Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. Am J Hum Genet. 2002 May;70(5):1333-40

Dubé N, Cheng A, Tremblay ML. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1834-9

Olivier M, Hsiung CA, Chuang LM, Ho LT, Ting CT, Bustos VI, Lee TM, De Witte A, Chen YD, Olshen R, Rodriguez B, Wen CC, Cox DR. Single nucleotide polymorphisms in protein tyrosine phosphatase 1beta (PTPN1) are associated with essential hypertension and obesity. Hum Mol Genet. 2004 Sep 1;13(17):1885-92

Lund IK, Hansen JA, Andersen HS, Møller NP, Billestrup N. Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J Mol Endocrinol. 2005 Apr;34(2):339-51

Ukkola O, Rankinen T, Lakka T, Leon AS, Skinner JS, Wilmore JH, Rao DC, Kesäniemi YA, Bouchard C. Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism. Obes Res. 2005 May;13(5):829-34

Akasaki Y, Liu G, Matundan HH, Ng H, Yuan X, Zeng Z, Black KL, Yu JS. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem. 2006 Mar 10;281(10):6165-74

Burdon KP, Bento JL, Langefeld CD, Campbell JK, Carr JJ, Wagenknecht LM, Herrington DM, Freedman BI, Rich SS, Bowden DW. Association of protein tyrosine phosphatase-N1

polymorphisms with coronary calcified plaque in the Diabetes Heart Study. Diabetes. 2006 Mar;55(3):651-8

Coras R, Hölsken A, Seufert S, Hauke J, Eyüpoglu IY, Reichel M, Tränkle C, Siebzehnrübl FA, Buslei R, Blümcke I, Hahnen E. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther. 2007 Jun;6(6):1745-54

Meshkani R, Taghikhani M, Mosapour A, Larijani B, Khatami S, Khoshbin E, Ahmadvand D, Saeidi P, Maleki A, Yavari K, Nasoohi N, Adeli K. 1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population. Arch Med Res. 2007 Jul;38(5):556-62

Lu X, Malumbres R, Shields B, Jiang X, Sarosiek KA, Natkunam Y, Tiganis T, Lossos IS. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood. 2008 Nov 15;112(10):4098-108

Mertins P, Eberl HC, Renkawitz J, Olsen JV, Tremblay ML, Mann M, Ullrich A, Daub H. Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics. 2008 Sep;7(9):1763-77

Arias-Romero LE, Saha S, Villamar-Cruz O, Yip SC, Ethier SP, Zhang ZY, Chernoff J. Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells. Cancer Res. 2009 Jun 1;69(11):4582-8

Blanquart C, Karouri SE, Issad T. Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem Biophys Res Commun. 2009 Oct 2;387(4):748-53

Hernández MV, Wehrendt DP, Arregui CO. The protein tyrosine phosphatase PTP1B is required for efficient delivery of N-cadherin to the cell surface. Mol Biol Cell. 2010 Apr 15;21(8):1387-97

Yip SC, Saha S, Chernoff J. PTP1B: a double agent in metabolism and oncogenesis. Trends Biochem Sci. 2010 Aug;35(8):442-9

Ferrari E, Tinti M, Costa S, Corallino S, Nardozza AP, Chatraryamontri A, Ceol A, Cesareni G, Castagnoli L. Identification of new substrates of the protein-tyrosine phosphatase PTP1B by Bayesian integration of proteome evidence. J Biol Chem. 2011 Feb 11;286(6):4173-85

Haque A, Andersen JN, Salmeen A, Barford D, Tonks NK. Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell. 2011 Sep 30;147(1):185-98

Ng KW. Regulation of glucose metabolism and the skeleton. Clin Endocrinol (Oxf). 2011 Aug;75(2):147-55

This article should be referenced as such:

Leuzzi G, Calderone A, Castagnoli L. PTPN1 (protein tyrosine phosphatase, non-receptor type 1). Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6):412-416.